Mirati Therapeutics Reports Promising Data from Clinical Trials

Mirati Therapeutics reported late Thursday promising data from two ongoing clinical programs, including the Phase 1b and Phase 2 trials of glesatinib, a spectrum selective kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET, and the Phase 1b trial of sitravatinib, a receptor tyrosine kinase inhibitor for the treatment of genetically-selected NSCLC and other solid tumors. Shares were down 6% in the after hours session.

For glesatinib, the company said that the spray dried dispersion (SDD) formulation has thus far demonstrated improved tolerability versus the prior miglyol soft gel formulation. In MET Exon 14 deletion patients treated with the SDD formulation across both the Phase 1b and Phase 2 trials, glesatinib demonstrated promising activity, with an In MET Exon 14 deletion patients treated with the SDD formulation across both the Phase 1b and Phase 2 trials, glesatinib demonstrated promising activity. Tumor reduction was observed in 11 of 13 patients.

Leave a Comment